Alumis Inc. (NASDAQ:ALMS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Alumis Inc. (NASDAQ:ALMS) has earned an average recommendation of “Moderate Buy” from the twelve analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $40.30.

ALMS has been the topic of several research analyst reports. Chardan Capital upped their price objective on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, May 19th. Morgan Stanley reiterated an “overweight” rating and set a $39.00 target price on shares of Alumis in a research report on Friday, May 15th. Guggenheim boosted their price target on shares of Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Citigroup reissued a “buy” rating on shares of Alumis in a report on Tuesday, May 19th. Finally, Wells Fargo & Company raised their price objective on shares of Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research report on Friday, May 15th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Cormorant Asset Management LP lifted its holdings in shares of Alumis by 69.3% in the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock worth $35,483,000 after acquiring an additional 1,488,200 shares during the last quarter. PSP Research LLC bought a new position in shares of Alumis during the 4th quarter valued at $427,000. Grange Capital LLC bought a new position in shares of Alumis during the 4th quarter valued at $312,000. Los Angeles Capital Management LLC raised its position in Alumis by 32.9% in the 4th quarter. Los Angeles Capital Management LLC now owns 163,084 shares of the company’s stock worth $1,592,000 after purchasing an additional 40,383 shares during the period. Finally, AXQ Capital LP raised its position in Alumis by 35.8% in the 4th quarter. AXQ Capital LP now owns 26,417 shares of the company’s stock worth $258,000 after purchasing an additional 6,965 shares during the period.

Alumis Price Performance

Shares of NASDAQ ALMS opened at $26.50 on Friday. The firm has a market capitalization of $3.38 billion, a P/E ratio of -13.38 and a beta of -0.73. The stock’s 50-day simple moving average is $23.26 and its two-hundred day simple moving average is $22.85. Alumis has a twelve month low of $3.20 and a twelve month high of $30.60.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. As a group, research analysts anticipate that Alumis will post -2.87 EPS for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.